[Edaily Reporter KIM HYUNSIK ] The Disney+ original series "The Remarried Empress" has topped the global online video service (OTT) popularity rankings. (Photo: Still from “The Remarried Empress”)According to FlixPatrol, an OTT ranking website, on the 21st, “The Remarried Empress”ranked No. 1 in the global Disney+ TV show category as of the 20th. This achievement came just 17 days after its release. “The Empress of Remarriage” has topped the Disney+ TV show charts in 45 countries worldwide, including Japan, Taiwan, France, Spain, Brazil, and Mexico. It is gaining popularity not only in Asia but also in Europe and Latin America, where it has entered the top ranks. “The Remarried Empress” is a romance fantasy drama that follows the story of Navi, the Empress of the Dongdae Empire, as she demands that Emperor Sobiesh—who has notified her of their divorce—approve her remarriage to Prince Heinrich of the Western Kingdom. It is based on the webtoon of the same name, which has recorded approximately 3 billion cumulative views worldwide. Actress Shin Min-a plays the role of Nabie, while Joo Ji-hoon portrays Sobiesh, Lee Jong-suk plays Heinrich, and Lee Se-young plays Rasta. Interest in the series has also extended to the cast. According to Google Trends, from the 3rd to the 11th, searches related to Shin Min-a, Joo Ji-hoon, Lee Jong-suk, and Lee Se-young were conducted worldwide in various countries, including Australia, Singapore, Chile, Vietnam, and Indonesia. “The Remarried Empress” is a 10-episode series, and episodes 1 through 8 have already aired. Episodes 9 and 10 will be released on the 25th.
This week (November 16–20), startups in various fields—including robotics, image analysis, and business platforms—secured investments from venture capital (VC) firms and accelerators (ACs). In particu…
Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penet…